Close Menu

Biocartis

For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019. 

The firm said that overall cartridge volumes in Q3 were back at pre-pandemic levels, and that it is on track to achieve targeted 30 percent growth for full-year 2020.

The PCR assay, which runs on the firm's Idylla platform, detects SARS-CoV-2 RNA in nasopharyngeal swabs from patients suspected to have COVID-19.

The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness. 

The deal with GeneproDx will focus on thyroid cancer, while the agreement with Endpoint Health will focus on CDx development for critical illnesses.

The firms had planned to develop the assay on Biocartis' Idylla platform, which would have allowed customers to perform the assay locally in their own lab facilities.

The consortium seeks to accelerate research and clinical diagnostic applications through collaboration with the ultimate goal of improving COVID-19 testing.

The assay will include a multiplexed panel of established and emerging biomarkers and will be the first RNA-based assay on the Idylla platform using FFPE samples. 

News items for in vitro diagnostics industry for the week of August 31, 2020.

Pages